Advertisement
U.S. markets closed

IO Biotech, Inc. (IOBT)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Visitors trend2W10W9M
1.47000.0000 (0.00%)
At close: 04:00PM EDT
Full screen
Add
Comparison
Indicators
Technicals
Corporate Events
Mountain
DrawTable View
Settings
AllAllFavoritesTextStatisticsTechnicalsFibonacciMarkingsLines
Loading interactive chart...
1D
Date Range
Interval:
1 min
  • GlobeNewswire

    IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

    Marjan Shamsaei, PharmD, Newly Appointed as Senior Vice President, Commercial Development and Portfolio Lead Brings Deep Oncology Product Commercialization ExpertiseNEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-I

  • GlobeNewswire

    IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

    Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor ActivityNEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place Apr

  • GlobeNewswire

    IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

    NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Mi